MARKET

HURA

HURA

TuHURA Biosciences
NASDAQ
1.900
-0.060
-3.06%
After Hours: 1.948 +0.048 +2.54% 19:43 03/13 EDT
OPEN
2.000
PREV CLOSE
1.960
HIGH
2.150
LOW
1.870
VOLUME
940.29K
TURNOVER
--
52 WEEK HIGH
4.440
52 WEEK LOW
0.4100
MARKET CAP
115.37M
P/E (TTM)
-1.1841
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at HURA last week (0302-0306)?
Weekly Report · 4d ago
Tuhura Biosciences Publishes Corporate Presentation on Overcoming Resistance to Cancer Immunotherapy
Reuters · 03/06 16:47
Weekly Report: what happened at HURA last week (0223-0227)?
Weekly Report · 03/02 10:30
TuHURA Biosciences Regains Nasdaq Compliance
Benzinga · 02/27 12:30
TUHURA BIOSCIENCES REGAINS COMPLIANCE WITH NASDAQ MINIMUM BID PRICE REQUIREMENT
Reuters · 02/27 12:30
TuHURA Biosciences CEO James Bianco to Present at Citizens Life Science Conference
Reuters · 02/24 22:20
TuHURA Biosciences Announces Participation in Upcoming Investor Conferences
Barchart · 02/24 16:20
Weekly Report: what happened at HURA last week (0216-0220)?
Weekly Report · 02/23 10:30
More
About HURA
TuHURA Biosciences, Inc. is a Phase III registration-stage immuno-oncology company developing novel technologies to overcome resistance to cancer immunotherapy. Its lead innate immune agonist, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors. It has initiated a single randomized placebo-controlled Phase III registration trial of IFx-2.0 administered as an adjunctive therapy to Keytruda (pembrolizumab) compared to Keytruda plus placebo in first-line treatment for advanced or metastatic Merkel Cell Carcinoma. It is leveraging its Delta Opioid Receptor technology to develop bi-specific antibody drug conjugates and antibody peptide conjugates targeting Myeloid Derived Suppressor Cells to inhibit their immune-suppressing effects on the tumor microenvironment to prevent T cell exhaustion and acquired resistance to checkpoint inhibitors and cellular therapies. It is also focused on the novel VISTA inhibiting mAb, known as TBS-2025.

Webull offers TuHURA Biosciences Inc stock information, including NASDAQ: HURA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, HURA stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading HURA stock methods without spending real money on the virtual paper trading platform.